SBI Securities Co. Ltd. Invests $313,000 in Tilray Inc (NASDAQ:TLRY)

SBI Securities Co. Ltd. purchased a new position in shares of Tilray Inc (NASDAQ:TLRY) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 235,653 shares of the company’s stock, valued at approximately $313,000.

A number of other institutional investors have also recently bought and sold shares of TLRY. BNP Paribas Financial Markets grew its holdings in Tilray by 1,314.1% during the third quarter. BNP Paribas Financial Markets now owns 1,819,494 shares of the company’s stock valued at $3,202,000 after purchasing an additional 1,690,827 shares during the period. Point72 Asset Management L.P. acquired a new position in Tilray during the third quarter valued at approximately $1,348,000. XTX Topco Ltd grew its holdings in Tilray by 1,079.7% during the third quarter. XTX Topco Ltd now owns 281,504 shares of the company’s stock valued at $495,000 after purchasing an additional 257,641 shares during the period. Alberta Investment Management Corp grew its holdings in Tilray by 58.2% during the fourth quarter. Alberta Investment Management Corp now owns 668,800 shares of the company’s stock valued at $884,000 after purchasing an additional 246,000 shares during the period. Finally, Thompson Davis & CO. Inc. acquired a new position in Tilray during the fourth quarter valued at approximately $249,000. Institutional investors and hedge funds own 9.35% of the company’s stock.

Tilray Stock Performance

Shares of TLRY opened at $0.72 on Thursday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.58 and a current ratio of 2.54. Tilray Inc has a twelve month low of $0.64 and a twelve month high of $2.97. The firm’s 50 day moving average price is $1.10 and its two-hundred day moving average price is $1.40. The firm has a market cap of $673.52 million, a P/E ratio of -2.39 and a beta of 2.13.

Tilray (NASDAQ:TLRY) last announced its quarterly earnings results on Friday, January 10th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.07). Tilray had a negative net margin of 30.95% and a negative return on equity of 4.40%. The company had revenue of $210.90 million during the quarter, compared to the consensus estimate of $216.34 million. The firm’s quarterly revenue was up 8.7% compared to the same quarter last year. On average, analysts forecast that Tilray Inc will post -0.2 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group boosted their price objective on shares of Tilray from $2.00 to $3.00 and gave the company a “buy” rating in a report on Monday, January 13th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $2.70.

About Tilray

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.